Exelon Corp. Raises Earnings Guidance - Quick Facts

Exelon Corp. (EXC) increased its year-end earnings guidance to $3.00 to $3.20 per share from $2.80 to $3.10 per share. Analysts polled by Thomson Reuters expect the company to report profit per share of $2.97. Analysts' estimates typically exclude special items.

Third quarter adjusted operating earnings increased to $1.04 per share from $0.92 per share, a year ago. On average, 16 analysts polled by Thomson Reuters expected the company to report profit per share of $0.87, for the quarter.

Third quarter operating revenue declined to $8.85 billion from $8.93 billion, previous year. Analysts expected revenue of $8.38 billion, for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT